Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569309 · ClinicalTrials.gov registry record · NA
Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00569309 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 30 participants.
The verdict
NCT00569309, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating patients who have undergone autologous stem cell transplant for high-risk lymphoma or multiple myeloma.
Interventions
- OTHER quality-of-life assessment
- BIOLOGICAL Streptococcus pneumoniae
- OTHER laboratory correlative studies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-12-12 |
| Est. Completion | 2011-07-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569309
The ClinicalTrials.gov registry entry for NCT00569309 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which quality-of-life assessment is the first listed.
NCT00569309 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569309 about?
NCT00569309 is a clinical study titled "Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma". RATIONALE: Vaccines may help the body build an effective immune response to kill cancer cells. Giving vaccine therapy after an autologous stem cell transplant may kill any cancer cells that remain after transplant. PURPOSE: This clinical trial is studying how well vaccine therapy works in treating ...
What is the current status of trial NCT00569309?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2007-12-12. Estimated completion is 2011-07-29.
What interventions are being tested in trial NCT00569309?
The interventions under investigation include: quality-of-life assessment (OTHER), Streptococcus pneumoniae (BIOLOGICAL), laboratory correlative studies (OTHER).
Who is sponsoring clinical trial NCT00569309?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.